A novel mutant PIK3R1 EY451delinsD breast cancer patient resistant to HER2-targeted therapy treated with everolimus: a case report.
Kainan WangYe HuLingzhi XuShanshan ZhaoChen SongSiwen SunXuelu LiMan LiPublished in: Molecular biology reports (2022)
mutation is associated with the resistance to anti-HER2 therapy, and that this mutation merits further investigation as a clinical biomarker and therapeutic target.